Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the first domestically developed trophoblast ...
Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for the treatment of certain patients with non-small cell lung cancer (NSCLC).